ورود
مقالات فارسیISIکنفرانسهاژورنالها

Myeloproliferative Neoplasms Associated with Mutation in JAK۲V۶۱۷F and Tyrosine Kinase Inhibitors as Therapeutic Strategy

محل انتشار: مجله تحقیق در پزشکی مولکولی، دوره: 3، شماره: 2
سال انتشار: 1394
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 47

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1882056

شناسه ملی سند علمی:

JR_REMJ-3-2_001

تاریخ نمایه سازی: 22 دی 1402

چکیده مقاله:

MPNs including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. JAK۲ tyrosine kinase mutation is the most common molecular lesion identified in ۹۰% of cases. JAK۲ is involved in EPO signaling pathway, and mutations in it lead to EPO-independent spontaneous phosphorylation. Most tyrosine kinase inhibitors (TKI) are small molecules that compete with ATP for binding the ATP-binding site in tyrosine kinase domains, since ATP is a source of phosphate groups used by Tks to phosphorylate the target protein.there are many TKI agent that are studing for treatment of the MPNs with JAK۲ tyrosine kinase mutation.the most important TKI drugs including CEP۷۰۱, CYT۳۸۷, LY۲۷۸۴۵۴۴, SB۱۵۱۸, TG۱۰۱۳۴۸, XL۰۱۹, INCB۱۸۴۲۴. Most important mechanism of them are reduse the splenomegaly, improvement of constitutional symptoms(improvement of bone marrow fibrosis and anemia). Although this drugs are useful but they have some side effect that common of them including Gastrointestinal disease (GI), diarrhea, nausea and vomiting, anemia, thrombocytopenia, thrombosis, leukocytosis, thrombocytosis, peripheral neuropathy, transient loss of blood pressure and lightheadedness.

کلیدواژه ها:

MPN ، JAK۲ ، TKI

نویسندگان

Kaveh Tari

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranDepartment of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Amir Atashi

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Reza Yarahmadi

Department of Laboratory Sciences, School of Paramedical Sciences, Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran

Saeid Abroun

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Abbas Hajifathali

Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Saeid Kaviani

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Masoud Soleimani

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Emanuel RM, Dueck AC, Geyer HL, Kiladjian J-J, Slot S, ...
  • Myeloproliferative disorders and its associated mutations [مقاله ژورنالی]
  • Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, ...
  • Santos FP, Verstovsek S. JAK۲ inhibitors: what's the true therapeutic ...
  • Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. ...
  • LaFave LM, Levine RL. JAK۲ the future: therapeutic strategies for ...
  • Zhao R, Xing S, Li Z, Fu X, Li Q, ...
  • Mannucci P. Polycythaemia vera and JAK۲ mutation. Internal and emergency ...
  • Tefferi A, Gilliland G. Classification of chronic myeloid disorders: from ...
  • Gäbler K, Behrmann I, Haan C. JAK۲ mutants (eg, JAK۲V۶۱۷F) ...
  • Melchiori L, Gardenghi S, Rivella S. Advances in hematology. ۲۰۱۰;۲۰۱۰ ...
  • Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. ...
  • Wilks A, Harpur A, Kurban R, Ralph S, Zürcher G, ...
  • Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, ...
  • Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, ...
  • Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, ...
  • James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau ...
  • Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, ...
  • Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: ...
  • Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, ...
  • Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, ...
  • Mascarenhas J, Mughal T, Verstovsek S. Biology and clinical management ...
  • Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: ...
  • Tefferi A, Thiele J, Vardiman JW. The ۲۰۰۸ World Health ...
  • Tefferi A. Myeloproliferative neoplasms ۲۰۱۲: The John M. Bennett ۸۰th ...
  • Krause DS, Van Etten RA. Tyrosine kinases as targets for ...
  • Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, ...
  • Gäbler K, Rolvering C, Kaczor J, Eulenfeld R, Méndez SÁ, ...
  • Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, ...
  • Fiskus W, Manepalli RR, Balusu R, Bhalla KN, editors. Synergistic ...
  • Harrison C, Verstovsek S, McMullin MF, Mesa R. Janus kinase ...
  • Wang JC, Chen C, Dumlao T, Naik S, Chang T, ...
  • Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, ...
  • DeAngelo DJ, Tefferi A, Fiskus W, Mesa RA, Paley CS, ...
  • Baffert F, Evrot E, Ebel N, Roelli C, Andraos R, ...
  • Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. ۲۰۰۸;۲۲(۱۰):۱۸۴۱-۸ ...
  • Vannucchi AM. How do JAK۲-inhibitors work in myelofibrosis: an alternative ...
  • Tefferi A, Kantarjian H, Pardanani A, Mesa R, Newton R, ...
  • Jedidi A, Marty C, Oligo C, Jeanson-Leh L, Ribeil J-A, ...
  • Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SMI, ...
  • Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, ...
  • Jatiani SS, Baker SJ, Silverman LR, Reddy EP. JAK/STAT pathways ...
  • Verstovsek S, Kantarjian H, Mesa RA, Cortes-Franco J, Pardanani AD, ...
  • Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen P, ...
  • Verstovsek S, Kantarjian H, Pardanani A, Thomas D, Cortes J, ...
  • Goh KC, Ong WC, Hu C, Hentze H, Liang AL, ...
  • Verstovsek S, Odenike O, Scott B, Estrov Z, Cortes J, ...
  • Purandare AV, Pardanani A, McDevitt T, Gottardis M, Lasho T, ...
  • Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, ...
  • Hart S, Goh K, Novotny-Diermayr V, Hu C, Hentze H, ...
  • Pardanani AD, Gotlib J, Jamieson C, Cortes J, Talpaz M, ...
  • Hood J, Doukas J, Martin M, Noronha G, Jamieson C, ...
  • Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, ...
  • Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, ...
  • Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, ...
  • Paquette R, Sokol L, Shah NP, Silver RT, List AF, ...
  • Shah NP, Olszynski P, Sokol L, Verstovsek S, Hoffman R, ...
  • Verstovsek S, Pardanani AD, Shah NP, Sokol L, Wadleigh M, ...
  • Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, ...
  • Pardanani A, Lasho T, Smith G, Burns C, Fantino E, ...
  • Pardanani A, George G, Lasho T, Hogan WJ, Litzow MR, ...
  • Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, ...
  • Ma L, Zhao B, Walgren R, Clayton JA, Blosser WD, ...
  • Florensa L, Bellosillo B, Arenillas L, Ma L, Walgren R, ...
  • Verstovsek S, Mesa RA, Salama ME, Giles JL, Pitou C, ...
  • Smith BD, Levis M, Beran M, Giles F, Kantarjian H, ...
  • Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, ...
  • Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, ...
  • Joosten LA, Leoni F, Meghji S, Mascagni P. Inhibition of ...
  • Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, ...
  • Pardanani A, Vannucchi A, Passamonti F, Cervantes F, Barbui T, ...
  • Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, ...
  • Dimopoulos MA, Jagannath S, Yoon S-S, Siegel DS, Lonial S, ...
  • Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, ...
  • Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH۵۸۹): a potent ...
  • Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, ...
  • Vannucchi AM, Guglielmelli P, Lupo L, Finazzi MC, Tozzi L, ...
  • Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, ...
  • Warsch W, Walz C, Sexl V. JAK of all trades: ...
    • نمایش کامل مراجع